Isodiol’s CBD beverage division, IsoBev, increases warehousing capabilities in Leesburg, FL and begins planning for expansion of its bottling division to increase its CBD beverage offerings
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), is providing an update on its recently acquired Florida based bottler, Azure. The Company is planning for increased warehousing capabilities and expansion of the production facility located in Leesburg, Florida.
IsoBev is the Company’s division that focuses on growing its beverage brand portfolio and contract manufacturing services for the beverage industry. With the expansion of the Leesburg warehouse, the Company will be able to facilitate its distribution needs in the South East market and provide Azure additional space to increase production for its customers that include Sysco, McArthur Dairy and Dean Foods.
The Company is also preparing to expand its beverage production capabilities for bottling in Leesburg to include a sparkling line and flavored line to meet the increased demands for functional beverages that include CBD.
“Given the growing global awareness of CBD and the Company’s belief that the 2018 Farm Bill is bound to pass in the United States, which will also bring clarity to the legality of hemp derived CBD, we believe the expansion of our Florida bottling facility positions the Company to further capitalize on this emerging segment of the beverage industry,” said Marcos Agramont, Isodiol International, CEO. “This expansion will increase our bottling capabilities and expand our product offerings to our sales channel partners,” added Agramont.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
Twitter: @Isodiolintlinc
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
KCSA Strategic Communications
www.KCSA.com
isodiol@kcsa.com
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.